热门资讯> 正文
神经分泌生物科学公司提供了来自4期KINECT-PRO开放标签研究事后分析的新数据
2025-09-23 20:35
- The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes.
- Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.
- Patients who achieved symptomatic remission had robust improvements across multiple patient-reported outcome measures after 24 weeks of INGREZZA treatment.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
